Home › Vaso-Occlusive Crises › Maryland
Vaso-Occlusive Crises clinical trials in Maryland
3 studies for Vaso-Occlusive Crises are looking for participants at sites in Maryland.
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- The Johns Hopkins University School of Medicine, Baltimore
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 28, 2026 · NCT06439082Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Maryland, Baltimore
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Aug 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07224360From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.